Natriuretic Peptide Or Derivative (e.g., Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Etc.) Patents (Class 514/12.4)
-
Publication number: 20130330366Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Publication number: 20130323244Abstract: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone.Type: ApplicationFiled: May 21, 2013Publication date: December 5, 2013Applicants: Vanderbilt University, Alexion Pharma International SarlInventors: Philippe CRINE, Florent Elefteriou
-
Patent number: 8598121Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: GrantFiled: May 8, 2012Date of Patent: December 3, 2013Assignee: Biomarin Pharmaceutical Inc.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
-
Patent number: 8586536Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: GrantFiled: December 14, 2011Date of Patent: November 19, 2013Assignee: Theravance, Inc.Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
-
Publication number: 20130303454Abstract: Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus.Type: ApplicationFiled: May 8, 2013Publication date: November 14, 2013Applicants: University of Iowa Research Foundation, Mayo Foundation for Medical Education and ResearchInventors: John C. Burnett, JR., Timothy M. Olson, Leonid V. Zingman, Denice Marie Hodgson-Zingman
-
Publication number: 20130296241Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.Type: ApplicationFiled: July 16, 2013Publication date: November 7, 2013Inventors: Horng H. Chen, John C. Burnett, Jr.
-
Publication number: 20130281375Abstract: Materials and methods related to using natriuretic polypeptides to reduce proliferation of smooth muscle cells, and to reduce or prevent restenosis.Type: ApplicationFiled: May 7, 2013Publication date: October 24, 2013Inventors: John C. Burnett, JR., Horng H. Chen, Ondrej Lisy
-
Patent number: 8551938Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 8, 2013Assignee: Alcon Research, Ltd.Inventors: Mark R. Hellberg, Iok-Hou Pang
-
Publication number: 20130259897Abstract: The invention provides crystalline forms of (R)-3-[N-(3?-chlorobiphenyl-4-ylmethyl)-N?—(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Inventors: Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
-
Publication number: 20130244937Abstract: Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described.Type: ApplicationFiled: September 2, 2012Publication date: September 19, 2013Applicants: NILE THERAPEUTICS, INC., MEDTRONIC, INC.Inventors: William Van Antwerp, Andrew J. L. Walsh, Lian Luo, Dianne L. Judd
-
Patent number: 8530422Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.Type: GrantFiled: August 23, 2012Date of Patent: September 10, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventors: Horng H. Chen, John C. Burnett, Jr.
-
Patent number: 8518876Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.Type: GrantFiled: April 27, 2011Date of Patent: August 27, 2013Assignee: Pharmaln CorporationInventors: Gerardo M. Castillo, Elijah M. Bolotin
-
Publication number: 20130209505Abstract: The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Inventor: Miroslav RAPTA
-
Publication number: 20130210724Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: April 12, 2013Publication date: August 15, 2013Applicant: Cerulean Pharma Inc.Inventor: Cerulean Pharma Inc.
-
Publication number: 20130196908Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: TRIGEMINA, INC.Inventor: TRIGEMINA, INC.
-
Publication number: 20130143816Abstract: Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.Type: ApplicationFiled: September 14, 2012Publication date: June 6, 2013Inventors: Shuchong Pan, Robert D. Simari
-
Patent number: 8455438Abstract: Materials and methods related to using natriuretic polypeptides to reduce proliferation of smooth muscle cells, and to reduce or prevent restenosis.Type: GrantFiled: December 29, 2009Date of Patent: June 4, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventors: John C. Burnett, Jr., Horng H. Chen, Ondrej Lisy
-
Publication number: 20130116181Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: January 4, 2013Publication date: May 9, 2013Applicant: Novartis AGInventor: Novartis AG
-
Patent number: 8436140Abstract: Tracers comprising an oligopeptide comprising a fragment of a natriuretic peptide, wherein the fragment comprises the sequence Arg-Ile-Asp-Arg-Ile (SEQ ID NO.: 1), and a signaling moiety, are disclosed. Further disclosed are methods of imaging atherosclerotic plaque by PET scanning or MRI using a tracer.Type: GrantFiled: May 22, 2009Date of Patent: May 7, 2013Assignee: Washington UniversityInventors: Pamela K. Woodard, Michael J. Welch, Geoffrey E. Woodard, Rafaella Rossin
-
Publication number: 20130096061Abstract: C-natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half-life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cyclic GMP. Vessel dilator was not studied previously on osteoblasts. CNP and vessel dilator were tested in dose-response studies enhanced human osteoblasts' proliferation, showing that vessel dilator has identical mechanisms of action to CNP but much longer biologic half-life and effects at lower concentrations. Vessel dilator exhibited therapeutic effect for use in human achondroplasia, short stature and osteoporosis by stimulating osteoblast proliferation.Type: ApplicationFiled: December 4, 2012Publication date: April 18, 2013Applicants: UNITED STATES DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF SOUTH FLORIDAInventors: University of South Florida, United States Department of Veterans Affairs
-
Publication number: 20130072431Abstract: Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Otago Innovation LimitedInventors: Christopher Joseph PEMBERTON, Arthur Mark Richards, Christopher John Charles, Maithri Siriwardena
-
Publication number: 20130045921Abstract: The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.Type: ApplicationFiled: August 27, 2010Publication date: February 21, 2013Applicant: IGISU COMPANY, LTDInventor: Kyoko Endo
-
Publication number: 20130023478Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.Type: ApplicationFiled: August 23, 2012Publication date: January 24, 2013Inventors: Horng H. Chen, John C. Burnett, JR.
-
Publication number: 20130012439Abstract: The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides.Type: ApplicationFiled: March 18, 2011Publication date: January 10, 2013Applicant: Daiichi Sankyo Company, LimitedInventors: Masaru Matsumoto, Shuji Takeda, Kyohei Nobori
-
Patent number: 8343919Abstract: The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.Type: GrantFiled: October 20, 2010Date of Patent: January 1, 2013Assignee: University of South FloridaInventor: David L. Vesely
-
Publication number: 20120315330Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: November 22, 2011Publication date: December 13, 2012Applicant: OREXO ABInventors: ANDERS PETTERSSON, CHRISTER NYSTROM
-
Publication number: 20120316114Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: ApplicationFiled: May 8, 2012Publication date: December 13, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
-
Publication number: 20120308587Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, R4, and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Roland Gendron, Adam D. Hughes
-
Publication number: 20120308588Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: May 18, 2012Publication date: December 6, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Jane Schmidt
-
Patent number: 8324162Abstract: This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal.Type: GrantFiled: August 8, 2007Date of Patent: December 4, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Robert D. Simari, Shuchong Pan, John C. Burnett, Jr., Horng H. Chen
-
Publication number: 20120276152Abstract: Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue.Type: ApplicationFiled: February 6, 2012Publication date: November 1, 2012Inventors: Syed Hossainy, John Stankus, Mikael Trollsas, Dariush Davalian
-
Publication number: 20120277155Abstract: Medical systems and methods for treating kidney disease alone, heart failure alone, chronic kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a natriuretic peptide such as Vessel Dilator to a subject. Methods for increasing and maintaining peptide levels at a certain concentration include direct peptide delivery via either an external or implantable programmable pump.Type: ApplicationFiled: February 7, 2012Publication date: November 1, 2012Applicant: MEDTRONIC, INC.Inventors: William P. VanAntwerp, Andrew J. L. Walsh, VenKatesh R. Manda, John Burnes
-
Patent number: 8293711Abstract: The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously for 18 hours to 72 hours.Type: GrantFiled: September 11, 2008Date of Patent: October 23, 2012Assignee: Pharis Biotech GmbHInventor: Wolf-Georg Forssmann
-
Patent number: 8283318Abstract: This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal.Type: GrantFiled: September 7, 2007Date of Patent: October 9, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Horng H. Chen, John C. Burnett, Jr.
-
Publication number: 20120238498Abstract: It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.Type: ApplicationFiled: January 21, 2012Publication date: September 20, 2012Applicants: Igisu Co., Ltd.Inventor: Kyoko Endo
-
Publication number: 20120220527Abstract: This document relates to methods and materials for treating diseases or disorders associated with elevated platelet counts (e.g., essential thrombocythemia, secondary thrombocytosis, congenital amegakaryocytic thrombocytopenia, sepsis, or asplenism) as well as methods and materials for treating diseases or disorders associated with elevated platelet adhesion to collagen (e.g., acute coronary syndromes, angina pectoris, chronic atherosclerosis, diabetes, or hypertension).Type: ApplicationFiled: January 27, 2012Publication date: August 30, 2012Inventors: Robert D. Simari, Sinny Delacroix
-
Publication number: 20120220528Abstract: Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.Type: ApplicationFiled: February 7, 2012Publication date: August 30, 2012Applicant: MEDTRONIC, INC.Inventors: William P. Van Antwerp, VenKatesh R. Manda, Andrew J. L. Walsh, John Burnes, Daron Evans, Hsiao Lieu
-
Publication number: 20120213806Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
-
Publication number: 20120213807Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: THERAVANCE, INC.Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Cameron Smith
-
Publication number: 20120208756Abstract: The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.Type: ApplicationFiled: July 23, 2010Publication date: August 16, 2012Applicant: IGISU CO., LTDInventor: Kyoko Endo
-
Publication number: 20120178689Abstract: Methods of treating heart failure, or decreasing blood pressure, comprising administering an NP at an appropriate dose, or in an amount sufficient to provide particular concentrations of NP, are provided.Type: ApplicationFiled: October 28, 2011Publication date: July 12, 2012Inventors: Daron EVANS, Hsiao Lieu
-
Publication number: 20120178668Abstract: The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.Type: ApplicationFiled: November 10, 2011Publication date: July 12, 2012Applicants: BAKER HEART RESEARCH INSTITUTE, THE UNIVERSITY OF QUEENSLANDInventors: Paul Alewood, Geoffrey A. Head, Brian Fry
-
Publication number: 20120164142Abstract: The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.Type: ApplicationFiled: December 23, 2011Publication date: June 28, 2012Applicant: Enobia Pharma Inc.Inventors: Philippe Crine, Simon Joubert, Marie Parat
-
Publication number: 20120157383Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: December 14, 2011Publication date: June 21, 2012Applicant: THERAVANCE, INC.Inventors: Roland GENDRON, Melissa FLEURY, Adam D. HUGHES
-
Publication number: 20120148529Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.Type: ApplicationFiled: May 12, 2010Publication date: June 14, 2012Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
-
Patent number: 8198242Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: GrantFiled: May 20, 2010Date of Patent: June 12, 2012Assignee: Biomarin Pharmaceutical Inc.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
-
Patent number: 8173596Abstract: A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample.Type: GrantFiled: May 16, 2005Date of Patent: May 8, 2012Assignee: The University of North Carolina at Chapel HillInventors: Michael F. Goy, Nicholas G. Moss, Xun Qian
-
Publication number: 20120053123Abstract: Materials and Methods related to making and using natriuretic polypeptides having a mutation in the ring portion of their structure.Type: ApplicationFiled: May 5, 2010Publication date: March 1, 2012Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: John C. Burnett, JR., Horng H. Chen
-
Publication number: 20120040902Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.Type: ApplicationFiled: September 23, 2011Publication date: February 16, 2012Inventors: Elaine Unemori, Sam L. Teichman, Gad Cotter, Dennis R. Stewart, Martha Jo Whitehouse
-
Publication number: 20120010142Abstract: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Inventors: John C. Burnett, JR., Timothy M. Olson